US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

210.53

-0.5100-0.24%

Pre-market: 210.00-0.5300-0.25%06:35 EDT

Volume:1.94M

Turnover:410.08M

Market Cap:10.68B

PE:33.35

High:212.62

Open:210.89

Low:209.84

Close:211.04

52wk High:217.12

52wk Low:144.65

Shares:50.75M

Float Shares:50.75M

Volume Ratio:1.36

T/O Rate:3.82%

Dividend:0.34

Dividend Rate:0.16%

EPS(TTM):6.31

EPS(LYR):35.34

ROE:24.54%

ROA:0.10%

PB:1.31

PE(LYR):5.96

Loading ...

Overview Company News Filings

Exchange-Traded Funds Rise, US Equities Mixed After Midday

MT Newswires Live

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

New precision medicine venture gives Syngenis added firepower

The West Australian

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Sector Update: Healthcare

MT Newswires Live

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138

Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/IBB/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"iShares Biotechnology ETF","latestPrice":210.53,"timestamp":1790798400000,"preClose":211.04,"halted":0,"volume":1939806,"hourTrading":{"tag":"盘前","latestPrice":210,"preClose":210.53,"latestTime":"06:35 EDT","volume":15,"amount":3162.2802,"timestamp":1790850917244,"change":-0.53,"changeRate":-0.002517,"amplitude":0.002517},"delay":0,"changeRate":-0.00241660348749048,"floatShares":50750000,"shares":50750000,"eps":6.311863,"marketStatus":"Pre-Mkt","change":-0.51,"latestTime":"10-01 06:43:13 EDT","open":210.89,"high":212.62,"low":209.84,"amount":410084027.89596003,"amplitude":0.013173,"askPrice":219.71,"askSize":50,"bidPrice":209.96,"bidSize":5,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":210.53,"sharesOutstanding":49450000,"nav":211.023541,"aum":11226452381.2,"dividendRate":0.001601,"bidAskSpread":0.000363,"preHourTrading":{"tag":"盘前","latestPrice":210,"preClose":210.53,"latestTime":"06:35 EDT","volume":15,"amount":3162.2802,"timestamp":1790850917244,"change":-0.53,"changeRate":-0.002517,"amplitude":0.002517},"postHourTrading":{"tag":"盘后","latestPrice":210.53,"preClose":210.53,"latestTime":"19:40 EDT","volume":10410,"amount":2191616.46,"timestamp":1790811644228,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3570641834940482,"impliedVol":0.2393,"impliedVolPercentile":0.58},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50750000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":1.3570641834940482,"shares":50750000,"dividePrice":0.3371,"high":212.62,"amplitude":0.013173,"preClose":211.04,"low":209.84,"week52Low":144.65,"pbRate":"1.31","psRate":"257.06","week52High":217.12,"institutionHeld":0,"latestPrice":210.53,"committee":-0.818182,"eps":6.311863,"divideRate":0.001601,"volume":1939806,"delay":0,"ttmEps":6.311863,"open":210.89,"prevYearClose":168.77,"prevWeekClose":209.77,"prevMonthClose":210.53,"prevQuarterClose":210.53,"fiveDayClose":206.6,"twentyDayClose":210.82,"sixtyDayClose":198.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-07-02","value":0.15606,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669126491","title":"Exchange-Traded Funds Rise, US Equities Mixed After Midday","url":"https://stock-news.laohu8.com/highlight/detail?id=2669126491","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669126491?lang=en_us&edition=fundamental","pubTime":"2026-09-23 01:10","pubTimestamp":1790097034,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV edged higher. Actively traded Invesco QQQ Trust (QQQ) added 0.5%.US equity indexes traded mixed, with materials leading gainers an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BITY","PSQ","CBOJ","UGL","BTCW","ETH","XAUUSD.FOREX","FBTC","CBTO","USO","ETH.USD.CC","BK4588","XLY","XRT","DULL","XSD","IAUM","NOCT","BITO","BK4550","BTCI","XBTY","BTCZ","BK4593","BETE","NAPR","YBTC","IYH","IYE","QQQM","BTCC","DGP","XLPD","SBIT","CBTA","BTF","RTH","TECL","DEFI","SCO","VIS","FAZ","CBXJ","BAR","DGZ","QQQ","BITX","CBXA","GBTC","BETH","OUNZ","BK4547","XLP","USG","EZBC","GLDY","RETL","SHNY","VDC","XLK","BTRN","SLV","ETHD","SIVR","ESK","QQQX","DFII","FGDL","VHT","SOXX","MAXI","YGLD","BRRR","BK4504","BAGY","QMAR","TETH","BITB","GLD","SQQQ","GLDM","BITU","BK4561","BTC","QID","ETCO","GPIQ","QDEC","XBI","ARKB","NDX","KGLD","BTC.USD.CC","SOXS","QBF","LABU","XAGUSD.FOREX","BPI","ZSL","CBTY","IAUI","IYJ","UNG","NJUL","CBOO","SGOL","BFAP","ETQ","MNRS","BTCL","IGM","XLF","BGLD","BCCC","CBTJ","IBB","BFJL","AGQ","SOXL","DZZ","IAU","NJAN","GLL","BITI","XLPU","CBOY","IGLD","BK4534","HODL","IYW","TQQY","BK4581","BTCO","TQQQ","XLE","EETH","QLD","IBIT","CBOA","XLI","BK4570","FAS","XLV","AAAU","UCO","CBXO","ETHT","SETH","CBXY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","PBE","LU2462157665.USD","IE0009355771.USD","LU0234570918.USD","BK4532","LU0889565916.HKD","IDNA","IE00BFTCPJ56.SGD","LU0058720904.USD","MAZE","VRTX","BBH","LU0289739699.SGD","GNMX","LU1559883803.SGD","BK4567","LU0079474960.USD","LU1815336091.USD","LU0432979614.USD","LU0256863811.USD","LU1585245621.USD","SGXZ57979304.SGD","LU2324357040.USD","LU2456880835.USD","IE00BZ9MQY76.HKD","LU1778281490.HKD","IE00B19Z3581.USD","LU2237438978.USD","LU2236285917.USD","TBXU","IE00B894F039.SGD","LU1069344957.HKD","IE0002141913.USD","XBI","IE00B19Z9Z06.USD","BK4588","IE00BJT1NW94.SGD","LU1430594728.SGD","BK4585","LU1093756168.USD","LU1674673428.USD","IE00B2B36J28.USD","LU2362541513.USD","LU2089984988.USD","BK4023","VERX","BIB","LU1035775433.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["HTEC","XJO.AU","GNMX","QFN.AU","BBOZ.AU","QRE.AU","XKO.AU","SLF.AU","GEAR.AU","EES","VAS.AU","HELX","PBE","IIGF.AU","BEAR.AU","OZR.AU","GDOC","STW.AU","IMLC.AU","BMED","ZYAU.AU","FDIF","BK4585","LFSC","ADHD","SYNB","VAP.AU","IOZ.AU","WDNA","OZF.AU","E200.AU","MEDX","XT","IISV.AU","JDOC","DACE.AU","IDNA","GIVE.AU","IBB","BK4588","XAO.AU","EIGA.AU","GNOM","TMAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669757123","title":"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669757123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669757123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:20","pubTimestamp":1790090418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN), Viking Therapeutics (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0122379950.USD","LU2242652126.USD","BK4566","IE00BJJMRZ35.SGD","LU0128526141.USD","LU2242646821.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","LABU","BK4139","BK4533","ELDN","TBXU","LU2089984988.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B2B36J28.USD","PJP","LU0289739699.SGD","SG9999001440.SGD","BIB","XLV","BK4137","LU1571399168.USD","IBB","LU0029874061.USD","BK4534","LU0868494617.USD","LU1983299246.USD","IE00BJT1NW94.SGD","BBH","LU0109394709.USD","BK4599","IE00B4R5TH58.HKD","LU2112291526.USD","PBE","THNR","XBI","OZEM","LU1057294990.SGD","AMGN","IE0009355771.USD","BK4588","VKTX","LU2468319806.SGD","HCSG","LU0058720904.USD","LU1061106388.HKD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123184","title":"Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123184","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123184?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:15","pubTimestamp":1790090123,"startTime":"0","endTime":"0","summary":"• Amgen shares rose following positive Phase 3 OASIZ 301 trial results for dazodalibep.  \n• The company reported an annual revenue of $36.75B and a net profit of $7.71B.  \n• Analysts hold an average price target of $389.14 with a Hold rating.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262180812-market-movers-amgn-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","TBXU","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0009355771.USD","LU2468319806.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0889565916.HKD","LU2242652126.USD","BK4534","LU1023059063.AUD","LU0868494617.USD","PBE","BK4588","AMGN","BK4581","IBBQ","LU2112291526.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","PJP","BIB","04332","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4566","BK4139","LU0109394709.USD","BK4533","BBH","IE00BFTCPJ56.SGD","BK4599","LU0289739699.SGD","BK4585","IBB","LU2242646821.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669821123","title":"Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669821123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669821123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:55","pubTimestamp":1790088920,"startTime":"0","endTime":"0","summary":"Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially und...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBE","LU2089984988.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU0122379950.USD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","BIB","LU2468319806.SGD","BK4534","IBB","BK4588","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1571399168.USD","BK4566","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","PJP","IE00BJJMRZ35.SGD","BK4581","LU2112291526.USD","IE0009355771.USD","BK4585","LU0109394709.USD","AMGN","LU0889565916.HKD","BK4533","TBXU","BK4599","SG9999001440.SGD","LU1983299246.USD","LU2242652126.USD","IBBQ","LU0868494617.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1674673691.USD","LU2362540622.SGD","LU0823416689.USD","IE0002141913.USD","PBE","SGXZ57979304.SGD","LU1069344957.HKD","LU0256863811.USD","GNMX","LU2362541513.USD","LU0289739699.SGD","VERX","LU2456880835.USD","IE00B19Z9P08.USD","TBXU","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","SG9999013999.USD","IE0002270589.USD","VRTX","LU0058720904.USD","LU0079474960.USD","LU1778281490.HKD","LU1093756325.SGD","IE00B894F039.SGD","IE0009355771.USD","IE00B19Z9Z06.USD","IDNA","LU0061475181.USD","BK4023","LU0757428866.USD","LU0320765992.SGD","BK4533","IE00B19Z3581.USD","LU2462157665.USD","LU1585245621.USD","LU1093756168.USD","BK4532","BBH","LU2089984988.USD","LU1559883803.SGD","IBBQ","LU1674673428.USD","LU1035775433.USD","IBB","BK4585","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00B894F039.SGD","IE00BJT1NW94.SGD","BIB","LU2456880835.USD","IE00BFTCPJ56.SGD","LU2462157665.USD","IE0002270589.USD","LU1585245621.USD","LU2362541273.HKD","VERX","BBH","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","BK4023","LU1778281490.HKD","LU0289739699.SGD","LU1559883803.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","BK4533","LU0432979614.USD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","SGXZ57979304.SGD","VRTX","IE0002141913.USD","LU2236285917.USD","IE0009355771.USD","IE00BZ9MQY76.HKD","TBXU","LU1815336091.USD","LU1674673428.USD","LU0109394709.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669470171","title":"Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2669470171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669470171?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:48","pubTimestamp":1790084894,"startTime":"0","endTime":"0","summary":"BUZZ-Amgen rises after autoimmune drug meets late-stage trial goal** Shares of drugmaker AmgenAMGN.Orise 2.4% to $402.69** Co says its experimental drug, dazodalibep, for Sjogren's diseasemet the main goalof reducing disease activity in a late-stage trial** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate** Co plans to present detailed results at an upcoming medical meeting** Including session's move, AMGN up 23.1% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU1057294990.SGD","BK4588","BK4581","LU2112291526.USD","BK4139","IE00B2B36J28.USD","BK4599","IE00B4R5TH58.HKD","PJP","LU0109394709.USD","BIB","LU1061106388.HKD","BK4585","LU2089984988.USD","IE00BJT1NW94.SGD","TBXU","BK4566","LU0320765992.SGD","BK4533","IE0009355771.USD","LU1571399168.USD","LU2242652126.USD","LU0889565916.HKD","AMGN","IBB","IE0002141913.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","BBH","BK4534","LU0289739699.SGD","LU2242646821.SGD","LU1023059063.AUD","LU0122379950.USD","LU0058720904.USD","PBE","IBBQ","SG9999001440.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147050","title":"Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147050?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:45","pubTimestamp":1790084715,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Amgen Inc::*AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026*AMGEN: DAZODALIBEP MEETS PRIMARY ENDPOI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSDcc0x9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","AMGN","IE00BJT1NW94.SGD","BIB","LU1571399168.USD","LU0122379950.USD","BK4566","BK4599","LU1061106388.HKD","BK4585","LU2089984988.USD","BK4588","LU0889565916.HKD","BK4533","LU2112291526.USD","BK4581","BBH","LU0109394709.USD","LU2242652126.USD","LU0868494617.USD","PJP","BK4534","IE0002141913.USD","IBBQ","LU2468319806.SGD","IBB","TBXU","LU1983299246.USD","LU2242646821.SGD","SG9999001440.SGD","BK4139","LU0289739699.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","PBE","IE00BJJMRZ35.SGD","LU0058720904.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147177","title":"Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147177?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:36","pubTimestamp":1790084178,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","IE0002141913.USD","BK4566","LU2112291526.USD","LU2468319806.SGD","IBB","IE00BJT1NW94.SGD","LU0109394709.USD","LU2242646821.SGD","BK4581","LU0889565916.HKD","LU1571399168.USD","LU0320765992.SGD","LU1061106388.HKD","LU2089984988.USD","TBXU","BK4585","BK4599","IBBQ","LU0868494617.USD","LU1023059063.AUD","LU0122379950.USD","IE00B4R5TH58.HKD","AMGN","IE00B2B36J28.USD","PBE","LU2242652126.USD","PJP","LU0289739699.SGD","BBH","LU1057294990.SGD","LU1983299246.USD","SG9999001440.SGD","BK4534","BK4139","BIB","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","IE00BJJMRZ35.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BIB","LU2468319806.SGD","BK4534","AMGN","LU0122379950.USD","TBXU","LU0320765992.SGD","LU2089984988.USD","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4566","BK4599","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4585","LU1057294990.SGD","BBH","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","IBBQ","IE00B4R5TH58.HKD","LU2242652126.USD","IE00BJT1NW94.SGD","PJP","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","LU1571399168.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","PBE","IE0009355771.USD","LU0234570918.USD","BK4532","LU0889565916.HKD","LU2468319806.SGD","IDNA","LU2417539215.USD","BK4139","IE00BFTCPJ56.SGD","VRTX","BBH","LU0289739699.SGD","GNMX","BK4567","LU0079474960.USD","LU1035775433.USD","LU0432979614.USD","LU0256863811.USD","LU1093756325.SGD","LU1674673691.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","LU2237438978.USD","LU2236285917.USD","TBXU","LU2362540622.SGD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU2362541273.HKD","IE0002141913.USD","IE00B19Z3B42.SGD","SG9999013999.USD","IE00B19Z9Z06.USD","LU0823416689.USD","BK4588","IE00BJT1NW94.SGD","LU0417517546.SGD","BK4585","LU1093756168.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2362541513.USD","LU2089984988.USD","BK4533","SG9999001176.SGD","BIB","LU0320765992.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBE","LU1061106388.HKD","LU0122379950.USD","IE00BJJMRZ35.SGD","BIB","LU0320765992.SGD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","LU2468319806.SGD","LU1023059063.AUD","AMGN","BBH","LU0109394709.USD","LU2089984988.USD","LU0289739699.SGD","LU1057294990.SGD","BK4566","LU1571399168.USD","PJP","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4585","LU1983299246.USD","BK4599","IBB","BK4533","IE0002141913.USD","BK4139","LU0889565916.HKD","TBXU","LU2112291526.USD","BK4534","BK4588","BK4581","LU0058720904.USD","IE00BJT1NW94.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669935142","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669935142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669935142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082001,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  0.2% lower and the iShares Biotechnology ETF  up 0.6%.Viking Therapeutics  shares were up more than 23% after the company said its subcutaneous VK2735 showed \"superior weight maintenance\" under less frequent dosing regiments compared to placebo over a 12-week period in a clinical study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BK4139","XBI","VKTX","BK4137","BK4585","BK4581","BK4588","HCSG","LABU","BK4599","LU0128526141.USD","OZEM","THNR","LU0029874061.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","SG9999001440.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU2089984988.USD","LU2242652126.USD","BK4566","LU0868494617.USD","BBH","LU1571399168.USD","BK4599","IE00BFTCPJ56.SGD","BIB","LU1983299246.USD","LU2112291526.USD","IBB","BK4585","BK4534","LU0058720904.USD","IE0002141913.USD","BK4533","BK4588","BK4581","LU0289739699.SGD","LU1061106388.HKD","IE00B4R5TH58.HKD","AMGN","IE0009355771.USD","LU0109394709.USD","LU0122379950.USD","LU2468319806.SGD","BK4139","LU1057294990.SGD","PJP","LU2242646821.SGD","TBXU","PBE","IBBQ","IE00BJT1NW94.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBB","BK4533","PBE","IE00BFTCPJ56.SGD","LU0122379950.USD","LU2112291526.USD","BK4566","LU0289739699.SGD","LU1571399168.USD","LU2468319806.SGD","LU2089984988.USD","LU0868494617.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU1057294990.SGD","SG9999001440.SGD","BK4585","IE0002141913.USD","LU1061106388.HKD","BK4139","IE00B4R5TH58.HKD","IE0009355771.USD","LU0320765992.SGD","BK4534","LU2242646821.SGD","LU0058720904.USD","LU0889565916.HKD","AMGN","BIB","IE00BJT1NW94.SGD","BK4599","BBH","BK4588","LU1983299246.USD","LU2242652126.USD","BK4581","LU1023059063.AUD","TBXU","IBBQ","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4023","IE0002270589.USD","SG9999013999.USD","BK4532","IE00BJJMRZ35.SGD","LU2362541513.USD","LU2417539215.USD","IE00B19Z3581.USD","IE0002141913.USD","BK4139","BK4533","LU0566484027.USD","TBXU","LU2362540622.SGD","IE00BZ9MQY76.HKD","LU2089984988.USD","LU1674673428.USD","SG9999001176.SGD","LU0079474960.USD","IE00B19Z9Z06.USD","LU1559883803.SGD","LU1069344957.HKD","BIB","GNMX","IBB","LU1674673691.USD","LU1093756325.SGD","LU2236285917.USD","IE00B894F039.SGD","LU1778281490.HKD","SG9999001176.USD","IE00BJT1NW94.SGD","BBH","PBE","BK4567","LU0061475181.USD","LU0757428866.USD","IE00B19Z9P08.USD","IDNA","VERX","LU1815336091.USD","IE0009355771.USD","BK4588","LU2468319806.SGD","SGXZ57979304.SGD","LU2324357040.USD","LU0058720904.USD","LU1035775433.USD","VRTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144262","title":"Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144262","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144262?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:27","pubTimestamp":1790080070,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) has issued an announcement. Adagene Inc., a platform-driven, clinical-stage biotechnology company listed on Nasdaq, specializes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XT","RSPH","DARP","IEIH","BK4585","BK4588","LCLG","IBB","LNGR","BBC","ADAG","NQmain","SYNB","JDOC","BBP","FHLC","BK4139","FWD","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669442921","title":"Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2669442921","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669442921?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:20","pubTimestamp":1790079649,"startTime":"0","endTime":"0","summary":"Filana Therapeutics (FLNA) announced that the U.S. Food and Drug Administration, FDA, has lifted the clinical hold on the Company’s investigational...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-announces-u-s-fda-lifted-clinical-hold-on-simufilam-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/filana-therapeutics-announces-u-s-fda-lifted-clinical-hold-on-simufilam-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","FLNA","SYNB","BK4585","IBB","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}